摘要
目的分析探究不同剂量米非司酮治疗子宫肌瘤的临床效。方法90例子宫肌瘤患者,以随机数字表法分为对照组和观察组,每组45例。对照组采取大剂量米非司酮治疗,观察组给予小剂量米非司酮治疗。比较两组患者治疗前后临床指标、用药效果及安全性。结果治疗后两组患者子宫肌瘤体积均小于治疗前,差异均具有统计学意义(P<0.05);但治疗前后,两组间子宫肌瘤体积比,差异均无统计学意义(P>0.05)。治疗后,观察组卵泡刺激素(FSH)为(10.36±0.84)μg/L,黄体生成素(LH)为(9.45±1.03)IU/L,雌二醇(E2)为(141.46±9.82)pmol/L,孕酮(P)为(5.64±0.72)nmol/L均低于对照组的(17.60±1.35)μg/L、(16.21±1.46)IU/L、(199.42±15.70)pmol/L、(8.53±1.28)nmol/L,差异均具有统计学意义(t=28.799、23.928、19.795、12.446,P<0.05)。观察组治疗总有效率为88.89%略低于对照组的91.11%,但差异无统计学意义(P>0.05)。观察组不良反应发生率为0低于对照组的8.89%,差异具有统计学意义(P<0.05)。结论在临床中针对子宫肌瘤患者,采取小剂量米非司酮治疗的效果与大剂量米非司酮相当,但在降低血清激素水平及安全性上更优,值得推广应用。
Objective To analyze and investigate the clinical efficacy of different doses of mifepristone in the treatment of uterine fibroids.Methods A total of 90 patients with uterine fibroids were divided into a control group and an observation group according to random numerical table,with 45 cases in each group.The control group was treated with high-dose mifepristone,and the observation group was treated with low-dose mifepristone.The clinical indicators before and after treatment,medication effects and safety were compared between the two groups.Results After treatment,the volume of uterine fibroids of the two groups were smaller than those before treatment,and the difference was statistically significant(P<0.05).Before and after treatment,there was no statistically significant difference in volume of uterine fibroids between the two groups(P>0.05).After treatment,the follicle stimulating hormone(FSH)was(10.36±0.84)μg/L,luteinizing hormone(LH)was(9.45±1.03)IU/L,estradiol(E2)was(141.46±9.82)pmol/L,and progesterone(P)was(5.64±0.72)nmol/L in the observation group;all were lower than(17.60±1.35)μg/L,(16.21±1.46)IU/L,(199.42±15.70)pmol/L,and(8.53±1.28)nmol/L in the control group,and the differences were statistically significant(t=28.799,23.928,19.795,12.446,P<0.05).The total effective rate in the observation group was 88.89%,which was slightly lower than 91.11%in the control group,but the difference was not statistically significant(P>0.05).The incidence of adverse reactions 0 in the observation group was lower than 8.89%in the control group,and the difference was statistically significant(P<0.05).Conclusion In clinical treatment of patients with uterine fibroids,low-dose mifepristone is comparable to high-dose mifepristone,but it is superior in terms of lowering serum hormone levels and safety,which is worth promoting and applying.
作者
刘丹
LIU Dan(Department of Pharmacy,Shenyang Maternity and Infant Hospital,Shenyang 110014,China)
出处
《中国现代药物应用》
2021年第17期184-186,共3页
Chinese Journal of Modern Drug Application
关键词
不同剂量
米非司酮
治疗
子宫肌瘤
Different doses
Mifepristone
Treatment
Uterine fibroids
